This trial is active, not recruiting.

Conditions end-stage renal disease, thrombocytopathy, cardiovascular diseases
Sponsor Hamilton Health Sciences Corporation
Collaborator St. Joseph's Healthcare Hamilton
Start date October 2004
End date December 2008
Trial size 40 participants
Trial identifier NCT00182156, Nephrology Divisional Funds


This study is examining the effects of short daily hemodialysis on platelet function, fluid volume control, arterial stiffness and patient quality of life, as compared to conventional hemodialysis.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective cross-sectional
conventional HD
short daily HD

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Patient is enrolled in short daily hemodialysis program - Patient is minimum of 18 years old Exclusion Criteria: - Patient is unable to consent due to language barrier - Patient is unable to consent due to cognitive difficulties - Patient refuses consent

Additional Information

Official title Cohort Study Examining the Effects of Short Daily Hemodialysis As Compared to Conventional Hemodialysis in Outpatients Treated at St Joseph's Healthcare, Hamilton
Principal investigator Azim Gangji, MD
Description Bleeding is a common cause of morbidity and mortality in patients with end stage renal disease. A major cause of uremic bleeding is due to platelet dysfunction. It has been theorized that in renal failure, toxins accumulate, some of which inhibit primary hemostasis. All aspects of normal platelet function are affected. Platelet function has previously been difficult to quantify but recently a novel test, the platelet function analyzer (PFA-100) has been determined to be both sensitive and specific in assessing platelet function. Conventional hemodialysis (CHD) has been shown to partially correct thrombocytopathy. Enhanced uremic clearance can now be attained through the use of short daily hemodialysis (SDHD). Cardiovascular disease is the most common cause of mortality in dialysis patients, accounting for 40% of deaths. Volume overload is associated with high blood pressure, left ventricular hypertrophy and elevated markers of inflammation and these factors have been associated with increased cardiovascular mortality. SDHD has been shown to control blood pressure and limit volume expansion. Pulse wave velocity (PWV) has been used to assess arterial compliance and reduction of arterial elasticity of large and small arteries which have been associated with cardiovascular outcomes.
Trial information was received from ClinicalTrials.gov and was last updated in June 2008.
Information provided to ClinicalTrials.gov by McMaster University.